Clinical Trial

Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label Phase 1/2 study of vimseltinib in patients with malignant solid tumors and tenosynovial giant cell tumor (TGCT). There will be 2 distinct parts in this study: Dose Escalation (Phase 1) and Expansion (Phase 2). Phase 1 will enroll both malignant solid tumor and TGCT patients. Phase 2 will comprise two cohorts (Cohort A and Cohort B) and will only enroll TGCT patients.
Protocol Amendment History 23 amendments
This ClinicalTrials.gov record has been amended 23 times since 2017-02-27; most recent amendment 2026-06-22.
Status change: Recruiting → Active, Not Recruiting 2023-10-05
Trial Details
NCT Number NCT03069469
Lead Sponsor Deciphera Pharmaceuticals, LLC
Conditions Advanced Malignant Neoplasm, Pigmented Villonodular Synovitis, Giant Cell Tumor of Tendon Sheath, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Diffuse
Enrollment 120 participants
Start Date 2017-02-16
Primary Completion 2028-08 (estimated)
Study Completion 2028-08 (estimated)
Updated on ClinicalTrials.gov 2026-06-25